AstraZeneca(US:AZN) Tai Ping Yang Zheng Quan·2025-06-25 15:06Investment Rating - The industry rating is neutral, indicating that the overall return is expected to be between -5% and 5% relative to the CSI 300 index over the next six months [9]. Core Insights - The pharmaceutical sector experienced a slight increase of +0.41% on June 25, 2025, underperforming the CSI 300 index by 1.03 percentage points, ranking 23rd among 31 sub-industries in the Shenwan classification [4]. - Among sub-industries, medical consumables (+1.34%), medical devices (+1.24%), and hospitals (+1.23%) performed well, while offline pharmacies (-0.10%), blood products (+0.10%), and in vitro diagnostics (+0.12%) lagged behind [4]. - AstraZeneca's two new drugs, AZD6234 and AZD9550, received clinical trial approval in China for long-term weight management in overweight or obese adults with at least one obesity-related comorbidity [5]. Summary by Sections Market Performance - On June 25, 2025, the pharmaceutical sector's performance was +0.41%, underperforming the CSI 300 index by 1.03 percentage points [4]. - The top three gainers were Huachang Technology (+13.48%), Shuyuan Pingmin (+6.80%), and Huitai Medical (+6.07%), while the top three losers were Yiming Pharmaceutical (-8.56%), Yong'an Pharmaceutical (-7.87%), and Beilu Pharmaceutical (-7.35%) [4]. Industry News - AstraZeneca's AZD6234 is a long-acting insulin receptor agonist approved for clinical trials in China, while AZD9550 is a synthetic GLP-1/glucagon dual receptor agonist, marking its first clinical approval in China [5]. - Yifan Pharmaceutical announced the approval for clinical trials of its biosimilar insulin injection [6]. - Shenzhou Cell and Hanyu Pharmaceutical also received approvals for their respective clinical trials and drug listings [6].